ANNEX  
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE 
OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES 
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE 
OF THE MEDICINAL PRODUCT TO BE ADDRESSED BY THE MEMBER STATES 
The Member States should ensure that the MAH provides an educational programme for Remicade to 
ensure  that  physicians  who  intend  to  prescribe  Remicade  to  paediatric  Crohn’s  disease  patients  are 
aware of: 
•  The risk of opportunistic infections and tuberculosis (TB) in patients treated with 
Remicade. 
•  The need to assess the risk of TB in patients prior to treating with Remicade. 
•  The risk of acute infusion related reactions and delayed hypersensitivity reactions. 
•  The risk of lymphoma and other malignancies. 
•  The patient alert card, which is to be given to patients using Remicade.  
•  That children may be at increased risk of developing infections and the need for 
immunisations to be up to date.  
2
 
 
 
 
 
 
 
 
 
 
 
 
